Gregory M. Springett

Author

Also Known As

G M Springett, G Springett, G. M. Springett, G. Springett, G.M. Springett, Gregory M Springett, Gregory M. Springett, Gregory Springett, Springett, Gregory

142

Publications

Citations

H-Index

Concepts

All Affiliations

Moffitt Cancer Center University of South Florida Sidney Kimmel Comprehensive Cancer Center Washington University in St. Louis University of Pittsburgh Medical Center

About

Gregory M. Springett is an author at Moffitt Cancer Center specializing in medicine, oncology, and radiation oncology.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	18	23	1.5K
2	Health Sciences	6	6	188
3	Cell Biology	3	3	91
4	Natural Sciences	1	1	41
5	Biochemistry	1	1	41

Gregory M. Springett

Publications

5.7K

Citations

H-Index

Page 1

	Year	Citations
A Family of cAMP-Binding Proteins That Directly Activate Rap1 Hiroaki Kawasaki, Gregory M. Springett, Naoki Mochizuki, Science	1998	1.4K
Safety and Survival With GVAX Pancreas Prime and <i>Listeria Monocytogenes</i>–Expressing Mesothelin (CRS-207) Boost Vaccines for Metastatic Pancreatic Cancer Dung T. Le, Andrea Wang‐Gillam, Vincent J. Picozzi, Journal of Clinical Oncology	2015	588
Axitinib plus gemcitabine versus placebo plus gemcitabine in patients with advanced pancreatic adenocarcinoma: a double-blind randomised phase 3 study Hedy L. Kindler, Tatsuya Ioka, D. J. Richel, The Lancet Oncology Gemcitabine Versus PlaceboOncologyPancreatic CancerGastrointestinal OncologyPharmacology	2011	393
A Rap guanine nucleotide exchange factor enriched highly in the basal ganglia Hiroaki Kawasaki, Gregory M. Springett, Shinichiro Toki, Proceedings of the National Academy of Sciences	1998	354
Stereotactic Body Radiation Therapy for Locally Advanced and Borderline Resectable Pancreatic Cancer Is Effective and Well Tolerated Michael D. Chuong, Gregory M. Springett, J. Freilich, International Journal of Radiation OncologyBiologyPhysics Surgical OncologyPancreatic CancerRadiation TherapyMedicineLocally Advanced	2013	341
Long-term outcomes of induction chemotherapy and neoadjuvant stereotactic body radiotherapy for borderline resectable and locally advanced pancreatic adenocarcinoma Eric A. Mellon, Sarah E. Hoffe, Gregory M. Springett, Acta Oncologica	2015	238
Phase I Dose-Escalation Trial of Checkpoint Kinase 1 Inhibitor MK-8776 As Monotherapy and in Combination With Gemcitabine in Patients With Advanced Solid Tumors Adil Daud, Michelle T. Ashworth, Jonathan Strosberg, Journal of Clinical Oncology	2015	184
Phase I trial of vorinostat and doxorubicin in solid tumours: histone deacetylase 2 expression as a predictive marker Pamela N. Münster, Douglas C. Marchion, Scott Thomas, British Journal of Cancer	2009	166
A Phase 1 Escalating Single-Dose and Weekly Fixed-Dose Study of Cetuximab: Pharmacokinetic and Pharmacodynamic Rationale for Dosing Paula M. Fracasso, Howard A. Burris, Matthew A. Arquette, Clinical Cancer Research	2007	148
Infection efficiency of T lymphocytes with amphotropic retroviral vectors is cell cycle dependent Gregory M. Springett, R C Moen, Stacie M. Anderson, Journal of Virology Infection EfficiencyViral ReplicationViral PersistenceCell Cycle DistributionHost Cell Cycle	1989	126

Page 1